Daniel Brennan
Stock Analyst at TD Cowen
(1.72)
# 3,123
Out of 4,843 analysts
20
Total ratings
33.33%
Success rate
3.08%
Average return
Main Sectors:
Stocks Rated by Daniel Brennan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QTRX Quanterix | Maintains: Hold | $14 → $16 | $5.20 | +207.69% | 2 | Nov 13, 2024 | |
| LAB Standard BioTools | Maintains: Buy | $2.75 → $2.5 | $1.01 | +147.52% | 3 | Oct 31, 2024 | |
| AVTR Avantor | Maintains: Buy | $30 → $29 | $12.91 | +124.63% | 5 | Oct 8, 2024 | |
| PACB Pacific Biosciences of California | Maintains: Buy | $12 → $2.5 | $0.96 | +159.42% | 2 | Apr 17, 2024 | |
| TMO Thermo Fisher Scientific | Maintains: Overweight | $613 → $670 | $402.82 | +66.33% | 1 | Feb 2, 2023 | |
| CRL Charles River Laboratories International | Upgrades: Buy | $177 → $200 | $135.63 | +47.46% | 2 | May 13, 2020 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $755 → $770 | $1,155.52 | -33.36% | 2 | May 8, 2020 | |
| EXAS Exact Sciences | Maintains: Buy | $135 → $115 | $56.28 | +104.34% | 3 | Apr 28, 2020 |
Quanterix
Nov 13, 2024
Maintains: Hold
Price Target: $14 → $16
Current: $5.20
Upside: +207.69%
Standard BioTools
Oct 31, 2024
Maintains: Buy
Price Target: $2.75 → $2.5
Current: $1.01
Upside: +147.52%
Avantor
Oct 8, 2024
Maintains: Buy
Price Target: $30 → $29
Current: $12.91
Upside: +124.63%
Pacific Biosciences of California
Apr 17, 2024
Maintains: Buy
Price Target: $12 → $2.5
Current: $0.96
Upside: +159.42%
Thermo Fisher Scientific
Feb 2, 2023
Maintains: Overweight
Price Target: $613 → $670
Current: $402.82
Upside: +66.33%
Charles River Laboratories International
May 13, 2020
Upgrades: Buy
Price Target: $177 → $200
Current: $135.63
Upside: +47.46%
Mettler-Toledo International
May 8, 2020
Maintains: Neutral
Price Target: $755 → $770
Current: $1,155.52
Upside: -33.36%
Exact Sciences
Apr 28, 2020
Maintains: Buy
Price Target: $135 → $115
Current: $56.28
Upside: +104.34%